Sobetirome

Sobetirome was developed as a thyroid hormone mimic with preference for receptor β, aiming to keep hepatic lipid effects while reducing unwanted cardiac stimulation [1]. In rats and cynomolgus monkeys it lowered cholesterol; in a seven-day monkey experiment both GC-1 and T3 reduced body weight by about 4%, while GC-1 did not cause the tachycardia seen with T3 [6]. This is animal evidence, not a human fat-loss trial.

In genetically obese mice, GC-1 produced a large rise in energy expenditure, body temperature and subcutaneous-fat UCP1, with fat loss and improved glucose testing in that experiment [2]. An implanted device delivering GC-1 continuously to diet-induced obese mice also reduced weight, fat mass, cholesterol and glucose over 24 days [3].

Results were not uniformly favorable. In ob/ob mice, lower-dose GC-1 cleared liver fat but raised fasting glucose and insulin, whereas a higher dose improved glucose tolerance [4]. In high-fat-fed rats it cut liver triglycerides by 75% yet impaired hepatic insulin sensitivity and caused fasting hyperglycemia [5]. Lipid lowering and glucose improvement cannot be treated as the same outcome.

GC-1 activates thyroid hormone receptor β in a tissue-dependent way. Human hepatocyte-derived cells showed induction of CPT1A, a fatty-acid oxidation gene [7]. In mice it strongly induced UCP1 and mitochondrial genes in subcutaneous white adipocytes, while classical brown-fat activity fell; isolated white adipocytes also increased respiration [2]. The mouse response may therefore depend on white-fat thermogenesis rather than ordinary brown-fat activation.

Selectivity is relative, not absolute. A mouse study found suppressed TSH during continuous GC-1 exposure [3], and a bone-development experiment showed that receptor β selectivity did not remove all skeletal effects [8].

Human safety for a fat-loss regimen is unknown. Early human cholesterol development has been described in reviews, but a peer-reviewed primary trial report with body-composition and safety outcomes was not located [1][9]. Rodent data show thyroid-axis suppression [3] and a dose-dependent risk of worse glycemia despite reduced liver fat [4][5]. The apparent cardiac sparing versus T3 in short animal studies does not establish long-term safety in people [6].